Does the media favor FTH or TNXP?

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 2 mentions for Sensei Biotherapeutics. Tonix Pharmaceuticals' average media sentiment score of 1.28 beat Sensei Biotherapeutics' score of 0.96 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RIGL or TNXP?

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 6 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Tonix Pharmaceuticals' score of 1.28 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TNXP or PHAR?

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Pharming Group. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 4 mentions for Pharming Group. Tonix Pharmaceuticals' average media sentiment score of 1.28 beat Pharming Group's score of 1.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AURA or TNXP?

In the previous week, Aura Biosciences and Aura Biosciences both had 6 articles in the media. Aura Biosciences' average media sentiment score of 1.77 beat Tonix Pharmaceuticals' score of 1.28 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NGNE or TNXP?

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 4 mentions for Neurogene. Neurogene's average media sentiment score of 1.76 beat Tonix Pharmaceuticals' score of 1.28 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tonix Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tonix Pharmaceuticals (TNXP) Competitors

$13.59 +0.03 (+0.22%)

As of 08/28/2026 04:00 PM Eastern

Compare

TNXP vs. FTH, RIGL, PHAR, AURA, and NGNE

Should you buy Tonix Pharmaceuticals stock or one of its competitors? Tonix Pharmaceuticals's main competitors and comparable companies include Sensei Biotherapeutics (FTH), Rigel Pharmaceuticals (RIGL), Pharming Group (PHAR), Aura Biosciences (AURA), and Neurogene (NGNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tonix Pharmaceuticals compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 2 mentions for Sensei Biotherapeutics. Tonix Pharmaceuticals' average media sentiment score of 1.28 beat Sensei Biotherapeutics' score of 0.96 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sensei Biotherapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Tonix Pharmaceuticals	$13.11M	17.78	-$124.02M	-$12.94	N/A

Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Sensei Biotherapeutics currently has a consensus price target of $55.00, indicating a potential upside of 62.53%. Tonix Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 80.28%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Sensei Biotherapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Tonix Pharmaceuticals' return on equity of -68.99% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Summary

Tonix Pharmaceuticals beats Sensei Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Tonix Pharmaceuticals' net margin of -548.64%. Rigel Pharmaceuticals' return on equity of 22.95% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 6 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Tonix Pharmaceuticals' score of 1.28 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals presently has a consensus target price of $59.00, suggesting a potential upside of 26.94%. Tonix Pharmaceuticals has a consensus target price of $24.50, suggesting a potential upside of 80.28%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rigel Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Rigel Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$276.79M	3.11	$367.02M	$16.32	2.85
Tonix Pharmaceuticals	$13.11M	17.78	-$124.02M	-$12.94	N/A

Summary

Rigel Pharmaceuticals beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Pharming Group?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Pharming Group. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 4 mentions for Pharming Group. Tonix Pharmaceuticals' average media sentiment score of 1.28 beat Pharming Group's score of 1.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	17.78	-$124.02M	-$12.94	N/A
Pharming Group	$376.13M	2.20	$2.85M	$0.12	97.50

Tonix Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market.

Pharming Group has a net margin of 2.51% compared to Tonix Pharmaceuticals' net margin of -548.64%. Pharming Group's return on equity of 3.40% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%
Pharming Group	2.51%	3.40%	1.90%

Tonix Pharmaceuticals currently has a consensus target price of $24.50, indicating a potential upside of 80.28%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 230.48%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Pharming Group beats Tonix Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

In the previous week, Aura Biosciences and Aura Biosciences both had 6 articles in the media. Aura Biosciences' average media sentiment score of 1.77 beat Tonix Pharmaceuticals' score of 1.28 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aura Biosciences has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Tonix Pharmaceuticals' return on equity of -68.99% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Aura Biosciences currently has a consensus price target of $17.50, indicating a potential upside of 136.49%. Tonix Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 80.28%. Given Aura Biosciences' higher possible upside, equities analysts plainly believe Aura Biosciences is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aura Biosciences has higher earnings, but lower revenue than Tonix Pharmaceuticals. Aura Biosciences is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Tonix Pharmaceuticals	$13.11M	17.78	-$124.02M	-$12.94	N/A

Summary

Tonix Pharmaceuticals beats Aura Biosciences on 8 of the 15 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 4 mentions for Neurogene. Neurogene's average media sentiment score of 1.76 beat Tonix Pharmaceuticals' score of 1.28 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tonix Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has higher earnings, but lower revenue than Tonix Pharmaceuticals. Neurogene is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	787.06	-$90.35M	-$5.03	N/A
Tonix Pharmaceuticals	$13.11M	17.78	-$124.02M	-$12.94	N/A

Neurogene has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. Neurogene's return on equity of -45.10% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-45.10%	-41.00%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Neurogene currently has a consensus target price of $83.67, suggesting a potential upside of 128.72%. Tonix Pharmaceuticals has a consensus target price of $24.50, suggesting a potential upside of 80.28%. Given Neurogene's higher possible upside, analysts clearly believe Neurogene is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Neurogene has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Neurogene beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNXP vs. The Competition

Export

Metric	Tonix Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$233.08M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.05	11.62	273.16	25.45
Price / Sales	17.78	1,291.80	604.48	76.58
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	1.05	16.53	12.98	6.14
Net Income	-$124.02M	-$22.80M	$3.48B	$348.86M
7 Day Performance	8.29%	-0.31%	0.13%	-0.80%
1 Month Performance	34.69%	9.80%	7.08%	4.13%
1 Year Performance	-54.13%	55.66%	24.67%	15.17%

Tonix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNXP Tonix Pharmaceuticals	4.3045 of 5 stars	$13.59 +0.2%	$24.50 +80.3%	-54.1%	$233.08M	$13.11M	N/A	50	Positive News Analyst Upgrade
FTH Sensei Biotherapeutics	4.2505 of 5 stars	$33.63 +4.8%	$55.00 +63.5%	N/A	$869.00M	N/A	N/A	40
RIGL Rigel Pharmaceuticals	4.5427 of 5 stars	$45.65 +0.9%	$59.00 +29.2%	+19.6%	$844.62M	$276.79M	2.80	160	Positive News Analyst Downgrade
PHAR Pharming Group	3.7341 of 5 stars	$11.93 +2.1%	$38.67 +224.1%	-21.2%	$844.41M	$376.13M	99.42	280	Short Interest Increase
AURA Aura Biosciences	2.8065 of 5 stars	$7.83 +0.8%	$17.50 +123.5%	+18.2%	$812.05M	N/A	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNXP) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. FTH, RIGL, PHAR, AURA, and NGNE

How does Tonix Pharmaceuticals compare to Sensei Biotherapeutics?

Summary

How does Tonix Pharmaceuticals compare to Rigel Pharmaceuticals?

Summary

How does Tonix Pharmaceuticals compare to Pharming Group?

Summary

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Summary

How does Tonix Pharmaceuticals compare to Neurogene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. FTH, RIGL, PHAR, AURA, and NGNE

How does Tonix Pharmaceuticals compare to Sensei Biotherapeutics?

Does the media favor FTH or TNXP?

Do insiders & institutionals believe in FTH or TNXP?

Which has stronger earnings and valuation, FTH or TNXP?

Which has more risk and volatility, FTH or TNXP?

Do analysts prefer FTH or TNXP?

Is FTH or TNXP more profitable?

Summary

How does Tonix Pharmaceuticals compare to Rigel Pharmaceuticals?

Is RIGL or TNXP more profitable?

Does the media favor RIGL or TNXP?

Do institutionals & insiders have more ownership in RIGL or TNXP?

Do analysts recommend RIGL or TNXP?

Which has more risk and volatility, RIGL or TNXP?

Which has stronger valuation and earnings, RIGL or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Pharming Group?

Does the media favor TNXP or PHAR?

Do institutionals and insiders believe in TNXP or PHAR?

Which has higher valuation and earnings, TNXP or PHAR?

Which has more risk & volatility, TNXP or PHAR?

Is TNXP or PHAR more profitable?

Do analysts prefer TNXP or PHAR?

Summary

How does Tonix Pharmaceuticals compare to Aura Biosciences?

Does the media prefer AURA or TNXP?

Is AURA or TNXP more profitable?

Which has more risk and volatility, AURA or TNXP?

Do analysts recommend AURA or TNXP?

Do insiders and institutionals believe in AURA or TNXP?

Which has higher valuation & earnings, AURA or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Neurogene?

Does the media favor NGNE or TNXP?

Which has preferable earnings & valuation, NGNE or TNXP?

Is NGNE or TNXP more profitable?

Do analysts recommend NGNE or TNXP?

Which has more risk & volatility, NGNE or TNXP?

Do institutionals and insiders hold more shares of NGNE or TNXP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools